Gilead CEO John Martin's 4.2 million shares--and 6.4 million vested options--have made him a billionaire, according to Bloomberg. Martin's tenure has seen the company build blockbuster revenue from its HIV franchise while creating a new standard of care in the hepatitis C arena. At the time Gilead ($GILD) bought out Pharmasset and the hep C drug that would go on to approval as Sovaldi, Martin got some flak for paying a whopping $11 billion for the biotech. Today, though, he's laughing all the way to the bank. He's already cashed in more than a half-billion dollars' worth of stock, which has quadrupled in value in a little more than two years. Gilead and Martin have also been criticized for charging $84,000 for a course of Sovaldi, but the company generally shrugs off its critics.
Caxton Associates LP is a New York-based trading and investment firm. Andrew E. Law is the Chairman and Chief Executive Officer. Caxton Associates' primary business is to manage client and proprietary capital through global macro hedge fund strategies. Assets are managed via a broad mandate to trade in a variety of global markets and instruments. Caxton Associates and its affiliates currently manage approximately $7.7 billion in assets. The firm was founded in 1983 by Bruce Kovner.
Caxton employs a staff of approximately 205 people, including traders, research analysts and administrative personnel in its offices in New York, London, Sydney and Princeton, NJ.
Caxton is a limited partnership formed under the laws of the State of Delaware and is registered with the U.S. Securities and Exchange Commission as an investment adviser under the Investment Advisers Act of 1940. The Firm is also a Commodity Pool Operator registered with the U.S. Commodity Futures Trading Commission and a member of the National Futures Association. In addition, Caxton is the sole shareholder of Caxton Europe Asset Management Limited (“CEAM”), a limited company formed under the laws of the United Kingdom. CEAM is the corporate member of Caxton Europe LLP, an investment manager registered with the U.K. Financial Conduct Authority.
very low volume trades..some institutional trades can do this easily and can manipulate price..this is not for retail investor..
Hey moron..the object is to sell into strength and take profits..not trying to sell at top